Eli Lilly and Company: Osteoporosis, Postmenopausal trials

The registry lists 25 Osteoporosis, Postmenopausal studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 3Phase 3 11Phase 4 10No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal WomenTerminatedNCT02337387Phase 1Results posted
• A Study of Blosozumab (LY2541546) in Postmenopausal Female ParticipantsCompletedNCT02109042Phase 1Results posted
• VERtebral Fracture Treatment Comparisons in Osteoporotic WomenCompletedNCT01709110Phase 4Results posted
• A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal WomenCompletedNCT01250145Phase 1Results posted
• Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic WomenCompletedNCT00927186Phase 4Results posted
• A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With TeriparatideCompletedNCT00557310Phase 4Results posted
• Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by OsteoporosisCompletedNCT00343252Phase 3Results posted
• A Study for Teriparatide in Severe OsteoporosisCompletedNCT00696644
• Effects of Teriparatide in the Treatment of Postmenopausal Women With OsteoporosisCompletedNCT00670501Phase 3
• Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With OsteoporosisCompletedNCT00670319Phase 3
• PTH Comparison in Post Menopausal WomenCompletedNCT00543218Phase 3
• A Study of the Treatment of Postmenopausal Women With OsteoporosisCompletedNCT00543023Phase 3
• Comparison Medications in the Treatment of Postmenopausal Women With OsteoporosisCompletedNCT00542984Phase 3
• Bone Marker Changes With Teriparatide/Postmenopausal OsteoporosisCompletedNCT00532545Phase 4
• Long Term Effects of Raloxifene Treatment on Bone QualityCompletedNCT00532428Phase 4
• Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or PlaceboCompletedNCT00532246Phase 4
• Study of Teriparatide in the Treatment of Postmenopausal Women With OsteoporosisCompletedNCT00532207Phase 3
• Study Comparing Arzoxifene With Raloxifene in Women After Menopause With OsteoporosisCompletedNCT00383422Phase 3
• Teriparatide and Strontium Ranelate Head-To-Head Comparison TrialCompletedNCT00239629Phase 4
• 2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal OsteoporosisCompletedNCT00191425Phase 4
• Effects of Arzoxifene on Bone Fractures and Incidence of Breast CancerCompletedNCT00088010Phase 3
• Effects of Arzoxifene on Bone Mass and the UterusCompletedNCT00085956Phase 3
• Effects of Teriparatide in Postmenopausal Women With OsteoporosisCompletedNCT00079924Phase 4
• Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With OsteoporosisCompletedNCT00046137Phase 3
• Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With OsteoporosisCompletedNCT00035256Phase 4